Bayer Faces a Three-Front Storm as Supreme Court, Trade Probe and Patent Battle Collide
Published on 06/21/2026 at 14:51 | Redaktion boerse-global.de
The coming weeks will determine whether Bayer’s recent recovery on the stock market has lasting power. Three separate fronts — a landmark US Supreme Court ruling on glyphosate, a formal trade investigation into German drug prices, and an escalating patent dispute over the blockbuster prostate cancer drug Nubeqa — are converging to create one of the most consequential periods for the company in years.
Shares closed at €37.81 on Friday, a weekly gain of 4.85%, and have now climbed more than 50% from the 52-week low of €25.09. The advance pushed the stock back above its 50-day moving average, a technical milestone that some traders see as a short-term buy signal. Yet the long-term target remains around €49.93, the 2026 high, and whether that is reachable depends almost entirely on how the legal and regulatory clouds lift.
Washington Levels a Trade Weapon at German Pharma
On 18 June, the Trump administration launched a formal Section 301 investigation against Germany, accusing it of keeping drug prices artificially low and forcing US patients to shoulder a disproportionate share of global pharmaceutical R&D costs. It marks the first time Washington has turned its drug-pricing agenda into a concrete enforcement action against a single European country.
The Office of the US Trade Representative will open a docket for written submissions on 25 June, with a public hearing scheduled for September. If tariffs are eventually imposed on German pharmaceuticals bound for the US, companies like Bayer, Boehringer Ingelheim and Merck KGaA — all of which maintain major production sites in Germany — would face a significant shift in their cost base. Trade Representative Jamieson Greer has hinted that higher reimbursement prices, along the lines of a recent US-UK agreement, could offer an alternative to punitive duties.
Should investors sell immediately? Or is it worth buying Bayer?
Nubeqa Legal Fight Heats Up
Separately, Bayer’s battle with Johnson & Johnson over its most important growth drug is intensifying. In February 2026, Bayer sued J&J and its Janssen Biotech unit, alleging that J&J’s prostate cancer drug Erleada is being marketed with flawed real-world data that unfairly positions it as superior to Bayer’s Nubeqa.
On 15 June, Bayer filed an amended complaint seeking a permanent injunction and damages. The court acknowledged a “plausible hypothesis” of methodological weaknesses in the J&J study but demanded empirical proof. With J&J refusing to hand over the full data set, Bayer is now preparing to compel its release through the discovery process. The outcome carries direct implications for Nubeqa’s market share in the concentrated prostate cancer space.
The Supreme Court Remains the Biggest Wild Card
Overshadowing both these issues is the long-running glyphosate saga. The US Supreme Court is expected to rule by the end of June in the Durnell case, which addresses a fundamental question: Can a company be found liable under state law when a federal agency, the EPA, has declared the product safe?
A favourable ruling for Bayer would render the vast majority of the roughly 65,000 remaining lawsuits effectively moot. An adverse decision would prolong the litigation wave for years. No single factor carries more weight for the stock. A separate development — a Missouri judge’s decision to send a multibillion-dollar settlement back to the lower court — has been interpreted by Bayer as a procedural victory, but a final hearing on that settlement is set for 9 July.
Bayer at a turning point? This analysis reveals what investors need to know now.
Operational Progress and Analyst Divergence
Away from the courtroom, Bayer is not standing still. The company’s AI-driven production plant in Leverkusen recently won a major industry award, and management expects the technology to cut manufacturing costs by 8% to 12%. Over the next five years, the additional gross profit from these savings is projected to land between €800 million and €1.2 billion, with a return on capital well above the industry average.
Analysts are split on what all this means for the share price. UBS rates the stock a buy with a €52 target, while Jefferies is more cautious with a “hold” equivalent and a €40 price objective. If the Supreme Court delivers a positive decision before the end of this month, the 50-day line could be decisively left in the dust. A negative outcome, by contrast, would likely pull the stock back towards the 200-day moving average at €36.22. The next few weeks will write the next chapter.
Ad
Bayer Stock: New Analysis - 21 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
